Wang Yu, Feng Zhang, Ying Xiao, Peiyu Wu, Liu Ning
Macau University of Science and Technology, Taipa, Macau, China.
Zhuhai College of Science and Technology, Zhuhai, China.
BMJ Open. 2025 Aug 19;15(8):e091845. doi: 10.1136/bmjopen-2024-091845.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease requiring long-term therapy, where adherence critically impacts outcomes. Non-adherence remains a significant barrier to disease control, particularly in China, where healthcare disparities persist.
This scoping review aimed to systematically map the existing evidence on the frequency, barriers and facilitators of treatment adherence among Chinese patients with SLE and to identify gaps to guide future research and interventions.
We included studies that assessed adherence to pharmacological and/or non-pharmacological SLE treatments among Chinese adults (≥18 years). Eligible designs included observational, interventional, qualitative and mixed-method studies published in English or Chinese.
10 electronic databases (eg, CNKI, PubMed, Web of Science, SCOPUS) were searched from inception to 27 March 2024, using MeSH terms and relevant keywords. Additional studies were retrieved through manual reference screening.
Data were extracted using a standardised form informed by the WHO multidimensional adherence framework. Key variables included study design, adherence measurement tools, frequency and categorised barriers/facilitators. Data were charted independently by two reviewers.
21 studies met inclusion criteria. Adherence was most often measured via self-report, especially Morisky Medication Adherence Scale-8 and Compliance Questionnaire for Rheumatology. Non-adherence ranged from 33.3% to 75.0%, reflecting measurement and population heterogeneity. Barriers were commonly patient-related, treatment-related and system-related, including fear of side effects, complex regimens, poor communication and financial burden. Facilitators included structured education, psychological support, simplified regimens and family support.
Treatment adherence among Chinese SLE patients is suboptimal and influenced by multidimensional factors. Culturally tailored, multilevel interventions-addressing education, communication and system-level barriers-are urgently needed. Adoption of standardised adherence measures and use of the WHO framework can improve cross-study comparability and guide targeted interventions.
OSF: osf.io/x5uzc; DOI: https://doi.org/10.17605/OSF.IO/GQWA7.
系统性红斑狼疮(SLE)是一种需要长期治疗的慢性自身免疫性疾病,治疗依从性对治疗结果至关重要。不依从仍然是疾病控制的重大障碍,在中国尤其如此,医疗保健差距依然存在。
本综述旨在系统梳理中国系统性红斑狼疮患者治疗依从性的频率、障碍和促进因素的现有证据,并找出差距,以指导未来的研究和干预措施。
我们纳入了评估中国成年人(≥18岁)对系统性红斑狼疮药物和/或非药物治疗依从性的研究。符合条件的设计包括以英文或中文发表的观察性、干预性、定性和混合方法研究。
从数据库建立至2024年3月27日,使用医学主题词和相关关键词检索了10个电子数据库(如中国知网、PubMed、科学网、Scopus)。通过手动参考文献筛选获取了其他研究。
使用由世界卫生组织多维依从性框架指导的标准化表格提取数据。关键变量包括研究设计、依从性测量工具、频率以及分类的障碍/促进因素。数据由两名评审员独立制表。
21项研究符合纳入标准。依从性最常通过自我报告来衡量,尤其是Morisky药物依从性量表-8和风湿病学依从性问卷。不依从率在33.3%至75.0%之间,反映了测量方法和人群的异质性。障碍通常与患者、治疗和系统相关,包括对副作用的恐惧、治疗方案复杂、沟通不畅和经济负担。促进因素包括结构化教育、心理支持、简化治疗方案和家庭支持。
中国系统性红斑狼疮患者的治疗依从性欠佳,且受多方面因素影响。迫切需要采取针对文化特点的多层次干预措施,解决教育、沟通和系统层面的障碍。采用标准化的依从性测量方法并使用世界卫生组织框架可提高跨研究的可比性,并指导有针对性的干预措施。
OSF:osf.io/x5uzc;DOI:https://doi.org/10.17605/OSF.IO/GQWA7 。